MaxCyte, Inc.
MXCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $39 | $41 | $44 | $34 |
| % Growth | -6.4% | -6.7% | 30.6% | – |
| Cost of Goods Sold | $7 | $5 | $5 | $4 |
| Gross Profit | $32 | $37 | $39 | $30 |
| % Margin | 81.6% | 88.5% | 88.5% | 89.2% |
| R&D Expenses | $22 | $24 | $20 | $15 |
| G&A Expenses | $30 | $30 | $26 | $19 |
| SG&A Expenses | $56 | $57 | $44 | $32 |
| Sales & Mktg Exp. | $27 | $27 | $19 | $13 |
| Other Operating Expenses | $4 | $4 | $3 | $1 |
| Operating Expenses | $83 | $85 | $67 | $48 |
| Operating Income | -$51 | -$48 | -$27 | -$18 |
| % Margin | -132.5% | -117% | -61.8% | -53.7% |
| Other Income/Exp. Net | $10 | $10 | $4 | -$1 |
| Pre-Tax Income | -$41 | -$38 | -$24 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$41 | -$38 | -$24 | -$19 |
| % Margin | -106.3% | -91.8% | -53.3% | -56.3% |
| EPS | -0.39 | -0.37 | -0.19 | -0.22 |
| % Growth | -5.4% | -94.7% | 13.6% | – |
| EPS Diluted | -0.39 | -0.37 | -0.19 | -0.22 |
| Weighted Avg Shares Out | 105 | 103 | 102 | 91 |
| Weighted Avg Shares Out Dil | 105 | 103 | 102 | 91 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $10 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $5 | $4 | $3 | $1 |
| EBITDA | -$46 | -$44 | -$25 | -$17 |
| % Margin | -120.1% | -106.9% | -55.7% | -49% |